Indications for SEEBRI NEOHALER:

Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.


For oral inhalation use only with Neohaler device; do not swallow caps. Administer at the same time of the day (AM + PM). Inhale contents of one capsule (15.6mcg) twice daily.


Not established.

Boxed Warning:


Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Severe milk protein hypersensitivity. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Severe renal impairment, including ESRD requiring dialysis. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacologic Class:

Long-acting anticholinergic.


Additive effects with concomitant other anticholinergic-containing drugs; avoid.

Adverse Reactions:

Upper respiratory tract infection, nasopharyngitis, urinary tract infection, sinusitis, oropharyngeal pain; paradoxical bronchospasm, hypersensitivity reactions.

Generic Availability:


How Supplied:

Blister pack—60 (w. one Neohaler device)